1. Home /
  2. Science


We Have a New AbbVie Price Target After Our Previous One Was Reached

Here's our fresh take on the shares.

Is This Pullback in Knowles Corp a Buying Opportunity?

Patient investors could go long KN at current levels.

Beaten-Down Biogen Could Finally Be Reaching an 'Interesting' Level

The shares have been cut in half over the last six months.

'A' Is for Buying: Agilent Is Resuming Its Uptrend

Here's how traders can play the stock.

Intuitive Surgical Is Rallying Ahead of Earnings

Traders could go long ISRG at current levels.

Medtronic Needs to Rebase Before Being Attractive Again

Stand aside and let things "shake out".

BNGO! Looks Like Bionano Genomics Could Be a Winner

Here's why the current weakness in Bionano Genomics could be a buying opportunity.

Intellia Therapeutics Busts Out of Resistance on Positive Trial News

The news sent shares of the genome editing company skyward after the stock had been basing for months.

Halfway Home and This Portfolio of Lovable Losers Keeps Delivering

The 2021 Tax Loss Selling Recovery Portfolio didn't do much in April but is soundly beating the market six months after inception.

CRISPR Therapeutics Could Suffer Further Steep Losses

Let's look over the charts and indicators.